|
GB8607683D0
(en)
|
1986-03-27 |
1986-04-30 |
Ici Plc |
Anti-tumor agents
|
|
GB8827305D0
(en)
|
1988-11-23 |
1988-12-29 |
British Bio Technology |
Compounds
|
|
SG64322A1
(en)
|
1991-05-10 |
1999-04-27 |
Rhone Poulenc Rorer Int |
Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
|
|
NZ243082A
(en)
|
1991-06-28 |
1995-02-24 |
Ici Plc |
4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
|
|
FI941572A7
(fi)
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
|
|
GB9300059D0
(en)
|
1992-01-20 |
1993-03-03 |
Zeneca Ltd |
Quinazoline derivatives
|
|
CA2372813A1
(en)
|
1992-02-06 |
1993-08-19 |
L.L. Houston |
Biosynthetic binding protein for cancer marker
|
|
US6177401B1
(en)
|
1992-11-13 |
2001-01-23 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften |
Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
|
|
GB9323290D0
(en)
|
1992-12-10 |
1994-01-05 |
Zeneca Ltd |
Quinazoline derivatives
|
|
US5455258A
(en)
|
1993-01-06 |
1995-10-03 |
Ciba-Geigy Corporation |
Arylsulfonamido-substituted hydroxamic acids
|
|
GB9314884D0
(en)
|
1993-07-19 |
1993-09-01 |
Zeneca Ltd |
Tricyclic derivatives
|
|
GB9314893D0
(en)
|
1993-07-19 |
1993-09-01 |
Zeneca Ltd |
Quinazoline derivatives
|
|
IL112248A0
(en)
|
1994-01-25 |
1995-03-30 |
Warner Lambert Co |
Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
|
|
GB9510757D0
(en)
|
1994-09-19 |
1995-07-19 |
Wellcome Found |
Therapeuticaly active compounds
|
|
GB9424233D0
(en)
|
1994-11-30 |
1995-01-18 |
Zeneca Ltd |
Quinazoline derivatives
|
|
US5863949A
(en)
|
1995-03-08 |
1999-01-26 |
Pfizer Inc |
Arylsulfonylamino hydroxamic acid derivatives
|
|
ES2153031T4
(es)
|
1995-04-20 |
2001-05-16 |
Pfizer |
Derivados del acido arilsulfonil hidroxamico como inhibidores de mmp y tnf.
|
|
US5880141A
(en)
|
1995-06-07 |
1999-03-09 |
Sugen, Inc. |
Benzylidene-Z-indoline compounds for the treatment of disease
|
|
GB9520822D0
(en)
|
1995-10-11 |
1995-12-13 |
Wellcome Found |
Therapeutically active compounds
|
|
GB9624482D0
(en)
|
1995-12-18 |
1997-01-15 |
Zeneca Phaema S A |
Chemical compounds
|
|
ATE225343T1
(de)
|
1995-12-20 |
2002-10-15 |
Hoffmann La Roche |
Matrix-metalloprotease inhibitoren
|
|
GB9603095D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
|
NZ331191A
(en)
|
1996-03-05 |
2000-03-27 |
Zeneca Ltd |
4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
|
|
EA199900021A1
(ru)
|
1996-07-13 |
1999-08-26 |
Глаксо, Груп Лимитед |
Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы
|
|
AR007857A1
(es)
|
1996-07-13 |
1999-11-24 |
Glaxo Group Ltd |
Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
|
|
HRP970371A2
(en)
|
1996-07-13 |
1998-08-31 |
Kathryn Jane Smith |
Heterocyclic compounds
|
|
KR20000067904A
(ko)
|
1996-07-18 |
2000-11-25 |
디. 제이. 우드, 스피겔 알렌 제이 |
매트릭스 메탈로프로테아제의 포스피네이트계 억제제
|
|
US5866702A
(en)
|
1996-08-02 |
1999-02-02 |
Cv Therapeutics, Incorporation |
Purine inhibitors of cyclin dependent kinase 2
|
|
US6790958B2
(en)
|
1996-08-02 |
2004-09-14 |
Robert T. Lum |
Purine inhibitors of cyclin dependent kinase 2 & IKBA
|
|
US6794390B2
(en)
|
1996-08-02 |
2004-09-21 |
Cv Therapeutics, Inc. |
Purine inhibitors of cyclin dependent kinase 2 & ikappabalpha
|
|
KR20000068248A
(ko)
|
1996-08-23 |
2000-11-25 |
디. 제이. 우드, 스피겔 알렌 제이 |
아릴설포닐아미노 하이드록삼산 유도체
|
|
JP3338064B2
(ja)
|
1997-01-06 |
2002-10-28 |
ファイザー・インク |
環状スルホン誘導体
|
|
NZ336840A
(en)
|
1997-02-03 |
2001-01-26 |
Pfizer Prod Inc |
Arylsulfonylamino hydroxamic acid derivatives useful in the treatment of tumor necrosis factor and matrix metalloproteinase mediated diseases
|
|
JP2000507975A
(ja)
|
1997-02-07 |
2000-06-27 |
ファイザー・インク |
Ｎ−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用
|
|
EP0960098A1
(en)
|
1997-02-11 |
1999-12-01 |
Pfizer Inc. |
Arylsulfonyl hydroxamic acid derivatives
|
|
JP2002511852A
(ja)
|
1997-05-07 |
2002-04-16 |
スージェン・インコーポレーテッド |
蛋白質キナーゼ活性の調節剤としての２−インドリノン誘導体
|
|
JP2002501532A
(ja)
|
1997-05-30 |
2002-01-15 |
メルク エンド カンパニー インコーポレーテッド |
新規血管形成阻害薬
|
|
US6255485B1
(en)
|
1997-08-07 |
2001-07-03 |
The Regents Of The University Of California |
Purine inhibitors of protein kinases, G proteins and polymerases
|
|
ES2289791T3
(es)
|
1997-08-22 |
2008-02-01 |
Astrazeneca Ab |
Derivados de oxindolilquinazolina como inhibidores de la angiogenesis.
|
|
AU744939B2
(en)
|
1997-09-26 |
2002-03-07 |
Merck & Co., Inc. |
Novel angiogenesis inhibitors
|
|
EP1028964A1
(en)
|
1997-11-11 |
2000-08-23 |
Pfizer Products Inc. |
Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
|
|
GB9725782D0
(en)
|
1997-12-05 |
1998-02-04 |
Pfizer Ltd |
Therapeutic agents
|
|
RS49779B
(sr)
|
1998-01-12 |
2008-06-05 |
Glaxo Group Limited, |
Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
|
|
GB9800575D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
|
GB9801690D0
(en)
|
1998-01-27 |
1998-03-25 |
Pfizer Ltd |
Therapeutic agents
|
|
PA8469501A1
(es)
|
1998-04-10 |
2000-09-29 |
Pfizer Prod Inc |
Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
|
|
PA8469401A1
(es)
|
1998-04-10 |
2000-05-24 |
Pfizer Prod Inc |
Derivados biciclicos del acido hidroxamico
|
|
SK287132B6
(sk)
|
1998-05-29 |
2009-12-07 |
Sugen, Inc. |
Farmaceutická kompozícia obsahujúca pyrolom substituovaný 2-indolinón, súprava obsahujúca uvedenú kompozíciu a použitie pyrolom substituovaného 2-indolinónu
|
|
US6232320B1
(en)
|
1998-06-04 |
2001-05-15 |
Abbott Laboratories |
Cell adhesion-inhibiting antiinflammatory compounds
|
|
JP3270834B2
(ja)
|
1999-01-27 |
2002-04-02 |
ファイザー・プロダクツ・インク |
抗がん剤として有用なヘテロ芳香族二環式誘導体
|
|
UA71945C2
(en)
|
1999-01-27 |
2005-01-17 |
Pfizer Prod Inc |
Substituted bicyclic derivatives being used as anticancer agents
|
|
EP1292591B1
(en)
|
2000-06-22 |
2005-02-02 |
Pfizer Products Inc. |
Substituted bicyclic derivatives for the treatment of abnormal cell growth
|
|
WO2002022605A1
(en)
|
2000-09-15 |
2002-03-21 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
|
AR042586A1
(es)
|
2001-02-15 |
2005-06-29 |
Sugen Inc |
3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
|
|
WO2002072549A1
(en)
|
2001-03-12 |
2002-09-19 |
Millennium Pharmaceuticals, Inc. |
Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
|
|
US20040235867A1
(en)
|
2001-07-24 |
2004-11-25 |
Bilodeau Mark T. |
Tyrosine kinase inhibitors
|
|
US20060009642A1
(en)
|
2001-10-12 |
2006-01-12 |
Irm Llc, A Delaware Limited Liability Company |
Methods for the synthesis of substituted purines
|
|
EP1578722A4
(en)
|
2001-10-12 |
2006-09-06 |
Irm Llc |
KINASEINHIBITOR SCAFFOLD AND METHOD FOR THE PRODUCTION THEREOF
|
|
US6949644B2
(en)
|
2001-10-12 |
2005-09-27 |
Irm Llc |
Methods for the synthesis of substituted purines
|
|
WO2004041285A1
(en)
|
2002-10-31 |
2004-05-21 |
Amgen Inc. |
Antiinflammation agents
|
|
WO2005016268A2
(en)
|
2003-08-08 |
2005-02-24 |
Mitochroma Research, Inc. |
Alimentary compositions and methods for metabolic modulation
|
|
US20070161582A1
(en)
|
2003-08-08 |
2007-07-12 |
Dusan Mijikovic |
Pharmaceutical compositions and methods for metabolic modulation
|
|
MXPA06001758A
(es)
|
2003-08-15 |
2006-08-11 |
Irm Llc |
Anilino purinas sustituidas en la posicion 6 utiles como inhibidores de rtk.
|
|
US20060029642A1
(en)
|
2004-08-03 |
2006-02-09 |
Dusan Miljkovic |
Methods and compositions for improved chromium complexes
|
|
GB0420719D0
(en)
|
2004-09-17 |
2004-10-20 |
Addex Pharmaceuticals Sa |
Novel allosteric modulators
|
|
FR2876583B1
(fr)
|
2004-10-15 |
2007-04-13 |
Centre Nat Rech Scient Cnrse |
Utilisation de derives de purines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
|
|
GB0502573D0
(en)
|
2005-02-08 |
2005-03-16 |
Topotarget As |
Therapeutic compounds
|
|
GB0526246D0
(en)
|
2005-12-22 |
2006-02-01 |
Novartis Ag |
Organic compounds
|
|
EP2012791A4
(en)
|
2006-02-07 |
2010-09-22 |
Conforma Therapeutics Corp |
7,9-DIHYDRO-PURIN-8-ONE AND RELATED ANALOGUES AS INHIBITORS OF HSP90
|
|
EP2008210A1
(en)
|
2006-03-15 |
2008-12-31 |
Csir |
Modulation of phosphoryl transferase activity of glutamine synthetase
|
|
EP2617423A1
(en)
|
2006-10-19 |
2013-07-24 |
Genzyme Corporation |
Purine derivatives for the treatment of cystic diseases
|
|
WO2008057402A2
(en)
|
2006-11-02 |
2008-05-15 |
Cytovia, Inc. |
N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof
|
|
KR20090112732A
(ko)
|
2007-01-26 |
2009-10-28 |
아이알엠 엘엘씨 |
플라스모듐 관련 질환의 치료를 위한 키나제 억제제로서의 퓨린 화합물 및 조성물
|
|
US8404674B2
(en)
*
|
2007-03-07 |
2013-03-26 |
Boehringer Ingelheim International Gmbh |
Substituted 9H-purin-2-YL compounds, compositions thereof and uses thereof
|
|
CA2695989A1
(en)
|
2007-08-10 |
2009-02-19 |
Glaxosmithkline Llc |
Certain nitrogen containing bicyclic chemical entities for treating viral infections
|
|
BRPI0818578A2
(pt)
|
2007-10-17 |
2015-07-21 |
Novartis Ag |
Derivados de purina como ligantes receptores de adenosina a1
|
|
US9089572B2
(en)
|
2008-01-17 |
2015-07-28 |
California Institute Of Technology |
Inhibitors of p97
|
|
EP2312945A4
(en)
|
2008-08-13 |
2012-05-09 |
Merck Sharp & Dohme |
PURE DERIVATIVES FOR THE TREATMENT OF MORBUS ALZHEIMER
|
|
TW201024298A
(en)
*
|
2008-09-23 |
2010-07-01 |
Palau Pharma Sa |
(R)-3-(N,N-dimethylamino)pyrrolidine derivatives
|
|
PE20100362A1
(es)
|
2008-10-30 |
2010-05-27 |
Irm Llc |
Derivados de purina que expanden las celulas madre hematopoyeticas
|
|
US8426428B2
(en)
*
|
2008-12-05 |
2013-04-23 |
Principia Biopharma, Inc. |
EGFR kinase knockdown via electrophilically enhanced inhibitors
|
|
WO2010118367A2
(en)
|
2009-04-10 |
2010-10-14 |
Progenics Pharmaceuticals, Inc. |
Antiviral pyrimidines
|
|
US9908884B2
(en)
*
|
2009-05-05 |
2018-03-06 |
Dana-Farber Cancer Institute, Inc. |
EGFR inhibitors and methods of treating disorders
|
|
FR2945747A1
(fr)
*
|
2009-05-25 |
2010-11-26 |
Centre Nat Rech Scient |
Composition pharmaceutique antitumorale comprenant un inhibiteur de cdks et un inhibiteur de la croissance cellulaire
|
|
TW201111385A
(en)
|
2009-08-27 |
2011-04-01 |
Biocryst Pharm Inc |
Heterocyclic compounds as janus kinase inhibitors
|
|
US9139592B2
(en)
|
2010-06-14 |
2015-09-22 |
Trt Pharma Inc. |
Modulators of Nrf2 and uses thereof
|
|
US20130172340A1
(en)
|
2010-06-22 |
2013-07-04 |
University of Central Flordia Research Foundation, |
Substituted 2-(9h-purin-9-yl) acetic acid analogues as inhibitors of stat3
|
|
WO2012051587A1
(en)
*
|
2010-10-14 |
2012-04-19 |
Ariad Pharmaceuticals, Inc. |
Methods for inhibiting cell proliferation in egfr-driven cancers
|
|
WO2012061303A1
(en)
*
|
2010-11-01 |
2012-05-10 |
Avila Therapeutics, Inc. |
Heteroaryl compounds and uses thereof
|
|
WO2012064706A1
(en)
*
|
2010-11-10 |
2012-05-18 |
Avila Therapeutics, Inc. |
Mutant-selective egfr inhibitors and uses thereof
|
|
EP2704572B1
(en)
*
|
2011-05-04 |
2015-12-30 |
Ariad Pharmaceuticals, Inc. |
Compounds for inhibiting cell proliferation in egfr-driven cancers
|
|
US8762299B1
(en)
|
2011-06-27 |
2014-06-24 |
Google Inc. |
Customized predictive analytical model training
|
|
EP2758402B9
(en)
*
|
2011-09-22 |
2016-09-14 |
Pfizer Inc |
Pyrrolopyrimidine and purine derivatives
|
|
CN103159742B
(zh)
|
2011-12-16 |
2015-08-12 |
北京韩美药品有限公司 |
5-氯嘧啶类化合物及其作为egfr酪氨酸激酶抑制剂的应用
|
|
WO2013106792A1
(en)
|
2012-01-13 |
2013-07-18 |
Acea Biosciences Inc. |
Heterocyclic compounds and uses as anticancer agents.
|
|
BR112015023020A2
(pt)
|
2013-03-14 |
2017-07-18 |
Pfizer |
combinação de inibidor de egfr t790m e inibidor de egfr para o tratamento de câncer pulmonar de células não-pequenas
|
|
US10884952B2
(en)
|
2016-09-30 |
2021-01-05 |
Intel Corporation |
Enforcing memory operand types using protection keys
|